Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05204329 · ClinicalTrials.gov registry record · Early Phase 1
Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
A Early Phase 1 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT05204329 is a Early Phase 1 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 9 participants.
The verdict
NCT05204329, a Early Phase 1 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of topical MSC Secretome eye drops. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use anterior segment Optical Coherence Tomography (OCT)/Scheimpflug Imaging, esthesiometry, and visual analogue scale (VAS) to assess treatment tolerability.
Interventions
- BIOLOGICAL MSC Secretome Eye Drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2024-01-24 |
| Est. Completion | 2024-11-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05204329
The ClinicalTrials.gov registry entry for NCT05204329 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MSC Secretome Eye Drops is the first listed.
NCT05204329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05204329 about?
NCT05204329 is a clinical study titled "Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease". This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of topical MSC Secretome eye drops. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will us...
What is the current status of trial NCT05204329?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2024-01-24. Estimated completion is 2024-11-08.
What interventions are being tested in trial NCT05204329?
The interventions under investigation include: MSC Secretome Eye Drops (BIOLOGICAL).
Who is sponsoring clinical trial NCT05204329?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.